TAURAS – T790 AURA ScreenFailure SOC Registry Study
Non Small Cell Lung Cancer
18 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Jul 2015 by AstraZeneca
No locations available
|NSCLC without T790M mutation|
NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
Other: Patient Reported Outcome (PRO)
Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
Other Name: Patient Reported Outcome (PRO)